Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvoxamine SCHEMBL35225 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL7339196 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL29014388 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL3863487 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL31022880 | 1.00 | MEN1 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL31495839 | 0.93 | MEN1 (0.87) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL27816994 | 0.91 | SLC6A4 (0.95) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL5569574 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL341698 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM | |
| Fluvoxamine SCHEMBL178609 | 0.91 | SLC6A4 (1.00) | MEN1LMNAKMT2ASMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315989-A1 | METHODS OF TREATING COVID-19 | WASHINGTON UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-20160000926-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140100183-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-04-10 | — | — | US | disclosed |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
| US-20090209480-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-08-20 | — | — | US | disclosed |
| US-7465462-B1 | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | ELAN PHARMA INTERNATIONAL LIMITED (IL) | 2008-12-16 | — | — | US | disclosed |
| US-20080206335-A1 | MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2008-08-28 | — | — | US | disclosed |
| US-20080138411-A1 | Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors | BIOVAIL LABORATORIES INTERNATIONAL S.R.L (BB) | 2008-06-12 | — | — | US | disclosed |
| US-20070293538-A1 | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1852111-A1 | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | ELAN CORPORATION, Plc (IE) | 2007-11-07 | — | — | EP | disclosed |
| EP-1178780-B1 | MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS | ELAN CORP PLC (IE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006001877-A2 | COMBINATION TREATMENT FOR NEURODEGENERATIVE DISORDERS COMPRISING R-FLURBIPROFEN | MYRIAD GENETICS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-0659082-B1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER LAMBERT CO (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5466696-A | Mixtures for treatment of alzheimer's disease | WARNER LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209480-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | SLC6A4 515/4885MEN1 1319/4885LMNA 2314/4885 |
| US-20140100183-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | SLC6A4 515/4885MEN1 1319/4885LMNA 2314/4885 |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | PMP22, INA, SMN1; SMN2 | SLC6A4 1266/4885MEN1 909/4885LMNA 1095/4885 |
| US-20070293538-A1 | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders | GRN, NLN, PSEN1 | SLC6A4 24/4885MEN1 4025/4885LMNA 1156/4885 |
| US-20240315989-A1 | METHODS OF TREATING COVID-19 | SIGMAR1, HTR1A, SGMS1 | SLC6A4 110/4885MEN1 2513/4885LMNA 1646/4885 |
| US-20160000926-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | INA, BDNF, PMP22 | SLC6A4 515/4885MEN1 1319/4885LMNA 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.